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INTRODUCTION
Hydroxyethyl starch (HES) and dextran are polysaccharide-based 
plasma volume expanders (PVE) which consist respectively of high 
molecular weight hydroxyethylglucose and glucose polymers with 
heterogeneous structure and properties. They are used for treatment 
of hypovolaemia and haemorrhage as plasma substitutes since they 
can significant increase plasmatic volume [14,27]. Nowadays, 
therapeutic use of dextran is less common compared to HES due to 
the increased risk for anaphylactic shock [11].
The use of PVEs is prohibited in sports because they can be used 
to prevent dehydration and because they can mask the use of eryth-
ropoietins or blood doping, since they can influence the blood pass-
port by decreasing haemoglobin and haematocrit values [20]. For 
these reasons, PVEs are included by the World Anti-Doping Agency 
(WADA) in the Prohibited List of substances and methods [26].
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ABSTRACT: Plasma volume expanders (PVEs) such as hydroxyethyl starch (HES) and dextran are misused in 
sports because they can prevent dehydration and reduce haematocrit values to mask erythropoietin abuse. 
Endogenous hydrolysis generates multiple HES and dextran oligosaccharides which are excreted in urine. 
Composition of the urinary metabolic profiles of PVEs varies depending on post-administration time and can 
have an impact on their detectability. In this work, different mass spectrometry data acquisition modes (full scan 
with and without in-source collision-induced dissociation) were used to study urinary excretion profiles of HES 
and dextran, particularly by investigating time-dependent detectability of HES and dextran urinary oligosaccharide 
metabolites in post-administration samples. In-source fragmentation yielded the best results in terms of limit of 
detection (LOD) and detection times, whereas detection of HES and dextran metabolites in full scan mode with 
no in-source fragmentation is related to recent administration (< 24 hours). Urinary excretion studies showed 
detection windows for HES and dextran respectively of 72 and 48 hours after administration. Dextran concentrations 
were above the previously proposed threshold of 500 µg · mL-1 for 12 hours. A “dilute-and-shoot” method for 
the detection of HES and dextran in human urine by ultra-high-pressure liquid chromatography-electrospray 
ionization-high resolution Orbitrap™ mass spectrometry was developed for this study. Validation of the method 
showed an LOD in the range of 10-500 µg · mL-1 for the most significant HES and dextran metabolites in the 
different modes. The method allows retrospective data analysis and can be implemented in existing Orbitrap™-
based doping control screening analysis.
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Aside from colorimetric microtitre plate methods [2,7,18], often 
used for screening due to the low cost and limited sample work up, 
detection of HES and dextran in doping analysis can be accomplished 
by mass spectrometric techniques including gas chromatography–
mass spectrometry (GC-MS) [15,16, 21,23], liquid chromatogra-
phy–mass spectrometry (LC-MS) [4,9,10,13] and matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-
TOF) [17]. Due to the polar nature and high molecular weight of 
HES and dextran, analysis by GC-MS requires an acidic hydrolysis 
step and a time-consuming derivatization step [15].
During the last decade, LC-MS has proven to be the ideal technique 
for doping control analysis of polar and high molecular weight com-
pounds [25]. Among the LC-MS methods described for the detection 
of PVEs in urine, those from Guddat [9] and Kolmonen [13] were 
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based on in-source fragmentation (isCID) to generate low mass frag-
ment ions from the sugar backbone and can be analyzed with 
a “dilute-and-shoot” strategy.
HES and dextran show a complex urinary excretion profile due 
to their macromolecular nature. HES is available as a mixture of 
chemically modified glucose polymers with an average molecular 
weight (MW) of 130 kDa, whereas dextran products have typically 
an average molecular weight of 40 (DEX 40) or 70 kDa (DEX 70) 
[14,19,22].
Since the nephron tubules only allow excretion of compounds 
with an MW less than 50 kDa, fractionation during urinary elimina-
tion can be observed as low MW components rapidly excreted in 
urine whereas high MW components are not filtered [1,12]. Once 
the high MW polysaccharides are cleaved by plasma amylase into 
smaller oligosaccharides (≈ 200-40 000 Da), they can be excreted 
in urine, with a speed inversely correlated to their size [13,17].
In this work, the urinary excretion profiles in time of HES and 
dextran as a matter of doping control were investigated using the 
conventional isCID approach. Additionally, since detection of HES 
and dextran oligosaccharides without in source CID (FSMS) is not 
described yet, the latter was also investigated.
Experiments were carried out by means of ultra-high pressure-
liquid chromatography coupled to Orbitrap™ high resolution mass 
spectrometry (UHPLC-HRMS). This technology has not yet been 
described for the detection of polysaccharide-based PVEs.
MATERIALS AND METHODS 
Chemicals. The commercial solution Voluven® (average molecular 
weight: 130 kDa; molar substitution: 0.4; concentration: 6% w/v) 
was used for HES. Dextran (average molecular weight: 40 kDa) was 
purchased from Fluka Chemie AG (Buchs, Switzerland).
Ammonium formate (NH4COOH) and HPLC-grade water (H2O) 
and acetonitrile (ACN) were from Biosolve (Valkenswaard, The Neth-
erlands). Formic acid (FA) and sodium azide (extra pure) were from 
Merck (Darmstadt, Germany). TFA was from Fluka (Bornem, Bel-
gium). The internal standard (2-hydroxypropyl)-β-cyclodextrin (HPCD) 
was obtained from Sigma–Aldrich (Bornem, Belgium). Internal stan-
dard solution containing 100 µg · mL-1 of HPCD was prepared in 
water. Gas used for the mass spectrometer was nitrogen (Alphagaz2-
grade) from Air Liquide (Desteldonk, Belgium).
Sample preparation
HES and dextran oligomers were obtained by hydrolysis with trifluo-
roacetic acid (TFA) 3M, adapting a procedure previously described 
by Gallego and Segura [6]. Briefly, hydrolyzed HES (10 mg · mL-1) 
was prepared by pipetting 150 µL of TFA in a tube containing 
500 µL of the commercial solution Voluven®. For dextran, 10 µL of 
10 mg · mL-1 solution were dissolved in 500 µL of 3M TFA. Both 
solutions were incubated for 30 minutes at 80°C. The hydrolysed 
material was dried under a stream of nitrogen at 60°C and redisolved 
in water to the desired concentration.
An aliquot of 100 µL of urine was transferred to an Eppendorf 
type vial containing 870 µL of 95:5 H2O:ACN, 1 mM NH4COOH, 
0.01% FA and 30 µL of HPCD. After centrifugation for 5 minutes 
at 10 000 rpm, 20 µL were injected into the chromatographic 
system.
Liquid chromatography
The liquid chromatographic system was an Accela LC (Thermo Sci-
entific, Bremen, Germany) equipped with degasser, Accela 1250 
pump, autosampler thermostated at 10°C and a heated column 
compartment. The column employed was a Zorbax SB-C8, 2.1 x 
50 mm and 1.8 µm particle size from Agilent Technologies (Böblin-
gen, Germany) thermostated at 25°C. The mobile phases were 1 mM 
NH4OAc/0.01% FAc in water (A) and 0.01% FA in acetonitrile (B). 
The gradient program was as follows: 100% A for 0.5 min, then 
decreased linearly to 20% in 7.0 min, and finally decreased lin-
early to 0% in 0.5 min and held at 0% for 1.5 min followed by an 
increase to the initial concentration of 100% A in 0.1 min. Equilib-
rium time was 2.4 min resulting in a total run time of 12 min. The 
flow rate was set constant at 250 µL · min-1 and the injection volume 
was 20 µL.
High-resolution mass spectrometry
The LC effluent was pumped to an Exactive benchtop, Orbitrap™-
based mass spectrometer (Thermo Scientific, Bremen, Germany) 
operated in the positive-negative polarity switching mode and 
equipped with a heated electrospray ion source (HESI). Nitrogen 
sheath gas flow rate and auxiliary gas were set at 60 and 30 (ar-
bitrary units), respectively. The capillary temperature was 350°C, 
the spray voltage 3 kV or -3 kV and the capillary voltage 30 V or 
-25 V, in positive or negative ion modes, respectively. The instru-
ment operated from m/z 150–3000 at 50,000 resolving power in 
FSMS and isCID at 80 eV. The automatic gain control (AGC) was 
set to 10e6. The data acquisition rate was 2 Hz. The Orbitrap™ 
performance in both positive and negative ionization modes was 
evaluated daily and when it failed, external calibration was per-
formed with Exactive Calibration Kit solutions (Sigma-Aldrich, St. 
Louis, USA and ABCR GmbH & Co. KG, Karlsruhe, Germany). 
A mass extraction window of 5 ppm was used.
Method validation
The validation was carried out following Eurachem validation guide-
lines [5]. Ten human urine samples, declared negative after routine 
doping analysis, were spiked with HES and dextran at a measure-
ment range from 10 to 1000 µg · mL-1. The limit of detection (LOD) 
was defined as the lowest level at which a diagnostic ion could be 
identified in all 10 urine samples with a signal-to-noise (S/N) ratio 
greater than 3 and a retention time difference of less than 0.3 min 
to the reference.
For dextran semi-quantitation, calibration curves from 10 to 
1000 µg · mL-1 (10, 50, 100, 500, 1000) were used. 30 µL of in-
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FIG. 1. MASS SPECTRA OF HES AND DEXTRAN IN FSMS AND ISCID MODE
ternal standard (100 µg · mL-1) were added. The precision of the 
method was checked by repeatability (intraday, n=6), intermediate 
precision (interday, n= 2), and reproducibility (interoperator, n= 2). 
Intraday repeatability was studied by calculating the percent relative 
standard deviation (% relative standard deviation, RSD) for 6 deter-
minations each of peak area of dextran (500 µg · mL-1) performed on 
the same day. The matrix effect was calculated by comparing the 
peak areas in reference samples, containing only water, with the peak 
areas of the 10 urine samples (spiked at 500 µg · mL-1), after analy-
sis in triplicate.
Selectivity was tested during the validation procedure. The 
10 blank urines used for determining detection capability were ana-
lyzed as described above.
Selectivity was further tested by analyzing urine samples contain-
ing common doping agents including diuretics, stimulants, 
β-blockers, β-agonists, narcotics, corticosteroids, anabolic steroids 
and non-steroidal anti-inflammatory drugs. Similarly to Kolmonen 
et al. [13], also urine samples from 20 diabetics were analyzed to 
evaluate abnormal excretion of endogenous oligosaccharides.
Excretion samples
Excretion urine samples of HES and dextran were collected at the 
Ghent University Hospital during a controlled study approved by the 
ethical committee (EC UZG 2006/178). Two patients received 500 
mL of Volulyte® (average molecular weight: 130 kDa; molar substi-
tution: 0.4; concentration: 6% w/v), and two patients received 500 
mL of Rheomacrodex® (average molecular weight: 40 kDa; concen-
tration: 10% w/v), both in a 2-hour period. Samples were collected 
before and until 5 days after administration.
RESULTS & DISCUSSION  
Mass spectrometry. The high number of molecular species originating 
from the in vivo hydrolysis of HES and dextran yields complex spectra 
with plenty of information (Figure 1). Investigation of the total ion 
current chromatograms of post-administration samples showed for 
HES and dextran typical ion clusters with constant m/z shifts, as al-
ready shown in previous works [3,6,9]. The clusters were observed 
in positive and in negative mode with different ion types for both PVEs, 
including molecular or adduct ions, in positive and negative mode.
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An in silico approach was applied to identify the components of 
the clusters observed. In the positive mode, predicted minimal m/z 
values were 181.0706 (single-charged ions) corresponding to 
a glucose (Glu) residue with no hydroxyethyl (HE) groups added. 
∆m/z values for the corresponding sodium (M+22.9892 Da), 
potassium (M+38.9631 Da) and ammonium (M+18.0338 Da) 
adducts were also calculated. In the negative mode, minimal 
m/z= 179.0561 (molecular ion) was predicted, and also formate 
adducts (M+44.9982 Da) were considered. ∆m/z= 162.0528 
was predicted for any additional Glu monomer. These calculations 
were valid for HES and dextran, since they both present a glucose 
backbone. Loss of water (∆m/z= -18.0106), a typical fragmenta-
tion product of polysaccharides, was also registered. For HES, ad-
ditional ∆m/z= of 44.0262 for an additional HE group was calcu-
lated.
HES and dextran showed very similar ionization properties. 
In fact, when detecting HES and dextran, multiple ions were re-
corded both in positive ([M+H]+, [M+Na]+, [M-K]+, [M-H2O+Na]+, 
[M+NH4]+) and in negative mode ([M-H]-, [M+FA]- and [M-H2O-H]-). 
Relative abundances of the ion types of interest varied significantly. 
Overall, positive mode yielded the best results. In particular, [M+H]+, 
[M+Na]+, [M+K]+ and [M-H2O+H]+ gave the best MS response 
and allowed for the longest detection window. For both PVEs, abun-
dances of Na+ and K+ adducts were generally comparable for the 
two different acquisition modes, whereas peaks of protonated ions 
were generally higher when isCID was used (Figure 2). Also negative 
ionization was observed, as previously described by Cmelik et al. [3], 
but showed less sensitivity than the positive mode.
Detection of metabolites in excreted urine in FSMS and isCID modes
As expected, a large number of metabolites were excreted in urine 
for both PVEs. The diagnostic ions for the metabolites covered the 
whole scan range. Therefore, three high-abundant ions were se-
lected as representative for low, medium and high m/z ions and 
FIG. 2. COMPARISON BETWEEN MS RESPONSE OF DIFFERENT ION TYPES FOR THE REPRESENTATIVE HES METABOLITE GLU2HE1 (LEFT) AND 
DEXTRAN METABOLITE GLU3 (RIGHT) IN REFERENCE STANDARD SOLUTIONS
FIG. 3. EXTRACTED ION CHROMATOGRAMS FOR HES AND DEXTRAN REPRESENTATIVE IONS SHOWING THE PRESENCE OF MULTIPLE PEAKS
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detectable both in FSMS and in isCID mode (respectively [Glu2HE1-
H2O+H]+ with m/z= 369.1396, [Glu5HE3-H2O+H]+ with 
m/z= 943.3500 and [Glu9HE4-H2O+H]+ with m/z= 1635.5875 
for HES, and [Glu3-H2O+H]+ with m/z= 487.1657, [Glu6+Na]+ 
with m/z= 1013.3157 and [Glu10+Na]+ with m/z= 1661.5270 
for dextran).
Full scan analysis without isCID allows for detection of intact 
oligosaccharides, produced by in vivo hydrolysis. Isobaric species 
can also be generated by isCID from bigger polysaccha-
rides (< 2-3 kDa).
Total ion current, but also extracted chromatograms for dextran 
(Figure 3), showed distorted peaks with a 2-minute peak width. This 
is most likely due to the broad molecular weight distribution of dex-
tran metabolites including molecules, including multiple isobaric 
isomers, with an MW of 1 kDa up to 50 kDa, eluting at different 
retention times. Additionally, the presence of a certain species is also 
dependent on the excretion stage. 
The presence of multiple metabolite populations for both HES 
and dextran has been previously described [13]. 
Figures 4 and 5 show chromatograms for HES and dextran in 
samples from excretion studies at different post-administration times. 
In the excretion samples, HES’ most abundant population eluted at 
2.8 min, whereas for dextran the most abundant peaks were usu-
ally recorded at 0.8 min (Figure 3).
Use of isCID yielded a higher MS response for all 6 investigated 
ions. This can be explained by the fact that, in isCID mode, the same 
fragment can be generated by a high number of metabolites with 
different masses, whereas for FS acquisition only a few isomeric 
oligosaccharides, with identical chemical formula, contribute to the 
signal.
Concerning HES, most of the detected species show similar nHE/
nGlu ratios, reflecting the fact that the Volulyte® degree of substitution 
is 0.4. [Glu2HE1-H2O+H]+ (molecular formula: C14H24O11, which 
reveals loss of a H2O molecule from monohydroxyethylated maltose) 
represents a very good marker for HES administration and was also 
described by previous research groups. [Glu2HE1-H2O+H]+ was also 
used in the work from Kolmonen et al. [13] and Guddat et al. [9], 
though in these papers it was referred to as [Glu2HE1+H]+, which 
has a theoretical m/z= 387.1502 and has been used by Mazzarino 
et al. [16]. The high abundance of this ion in FSMS mode demon-
strates that monohydroxyethylated maltoses are the main metabolites. 
Contemporarily, sensitive detection in isCID shows that fragment ions 
with the same m/z values are common as well. [Glu2HE1-H2O+H]+ 
was still detectable after 72 hours both with and without isCID, 
whereas [Glu5HE3-H2O+H]+ could be detected only in isCID mode 
after 24 hours. Larger metabolites and fragments such as [Glu9HE4-
H2O+H]+ were only detected in the excretion samples until 6 hours 
after administration (data not shown).
Dextran ions were all clearly detected after 3 and 12 hours, both 
with isCID and without isCID (Figure 5). They were not detected in 
FS mode after 24 hours, whereas the use of isCID prolonged the 
detection window up to 48 hours. This is in agreement with previ-
ous work, which showed that in the 0-24 h fraction up to 5 kDa 
is excreted and can be detected without isCID [13].
It can be concluded that contemporary detection in FS and isCID 
mode is particularly interesting since it can provide important infor-
mation on the administration time. Taking into account that the 
duration of volume expansion is 8-12 hours for HES and 6-12 hours 
for dextran [22], detection of multiple metabolites both with and 
without isCID can therefore discriminate whether the PVE has been 
administered on the same day of the doping control.
Method validation
HES
For the validation, 130 kDa HES was partially hydrolyzed to yield 
lower molecular weight HES. This was necessary because the 130 
kDa HES could not be detected without isCID because the high 
molecular weight species could not enter the mass spectrometer. 
Validation results for HES are presented in Table 1. Due to the pres-
ence of multiple peaks, it is very important to select the retention 
time window for the most abundant of them to increase sensitivity. 
In this case, the peak at 2.8 min was selected.
HES showed the lowest LOD of 10 µg · mL-1 for the ion [Glu2HE1-
H20+H]+ in isCID mode; this LOD is comparable to those from 
previous works [9,13,16]. A great difference was observed with 
FSMS where for the same ion an LOD of 500 µg · mL-1 was calcu-
lated. This difference in sensitivity has already been explained by the 
fact that, in isCID mode, the same fragment can be generated by 
TABLE 1. VALIDATION DATA
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several metabolites with higher masses, whereas for FSMS only 
a few isomeric oligosaccharides, with identical chemical formula, 
contribute to the signal. The matrix effect for HES was not significant, 
with even a slight trend to ion enhancement for all 3 ions (Table 1). 
No interferences were detected in blank samples, diabetics’ urine 
or urine containing other doping agents, showing excellent selectiv-
ity of the method.
Dextran
Similar to the validation of HES, dextran with an average molecular 
weight of 40 kDa yielded a poor signal when analyzed without 
isCID. Therefore, partial hydrolysis of dextran 40 kDa was also 
performed.
Compared to HES, selectivity is a bigger issue for dextran because 
physiopathological excretion of hexose-containing oligosaccharides 
can theoretically generate false positive results. To solve this problem, 
a threshold of 500 µg · mL-1 has been proposed for screening pur-
poses [9]. Indeed, several negative samples, analyzed with this 
method, showed an isCID signal from endogenous oligosaccharides 
with 10-100 fold lower signals than the suggested threshold 
(Figure 6b).
In FSMS mode, the molecular ion of quadruply hydroxypropylated 
β cyclodextrin at m/z= 1384.5685 was used for semi-quantitation, 
whereas the fragment ion corresponding to the dihydroxypropyl iso-
maltose at m/z= 441.1966 was selected.
 [Glu3-H2O+H]+ was selected among the numerous diagnostic 
ions for dextran semi-quantitation both in FSMS and isCID mode, 
providing the best compromise between sensitivity and linearity. 
The peak at 2.7 minutes was selected for semi-quantitation since the 
calculated dextran concentration allowed to confirm recent adminis-
tration (>500 µg · mL-1 after 12 hours), although early-eluting species 
are more abundant after 3 hours (Figure 5). However, once a suspi-
cious peak at 2.8 is detected, it is recommended to the analyst to 
check the whole elution window (0.6-2.7 min) to have further evidence 
before confirmation analysis.
Intraday repeatability, interday precision, and reproducibility were 
respectively 6.1%, 20.9% and 10.9% in the FMSM  mode, and 
7.1%, 9.9% and 8.3% in the isCID mode. The excretion study pre-
sented in this work confirmed that the threshold proposed by Guddat 
is reliable to discriminate between natural excretion of oligosaccharides 
and recent dextran administration (up to 12 hours). Despite the el-
evated concentration measured in FSMS, it was not possible to define 
a threshold for this acquisition mode since concentrations in negative 
samples were comparable to the quality control samples (Figure 6a).
It should be stated that semi-quantitative results can be affected 
by the choice of the reference standard that is being used. In any 
FIG. 3. SEMI-QUANTITATIVE DETERMINATION OF [GLU3-H2O+H]+ CONCENTRATION IN A REPRESENTATIVE 
BATCH OF ROUTINE SAMPLES (N= 50), COMPARED TO A QUALITY CONTROL SAMPLE SPIKED AT 500 μg · mL-1 
IN FSMS (A) AND ISCID (B) MODE AND 3, 12 AND 24 HOURS EXCRETION SAMPLES.
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case, the reference can represent only partially the composition of 
dextran metabolites in urine, especially since this evolves over time.
Observing the data from excretion results, several low and medium 
m/z diagnostic ions showed abundant MS signals and the best detec-
tion windows and can be used to estimate dextran concentration in 
the sample. Since the method is for screening purposes, one of these 
ions can be monitored in the first instance to reveal suspicious sam-
ples, similarly as described in other high-throughput screening anal-
yses [10]. In case a potential positive sample is detected, retrospec-
tive “post-targeted” data evaluation using multiple diagnostic ions is 
suggested before the necessary confirmatory analysis by partially 
methylated alditol acetates (PMAA) [24] or enzymatically derived 
isomaltose [8].
LOD in CID was well below the suggested threshold (50 µg · mL-1). 
Regression curves always showed R2> 0.90. Ion suppression in isCID 
was approximately 40%.
Another important issue was represented by samples from dia-
betic patients, which can lead to false positive results. In fact, as also 
described by Kolmonen et al. [13], high amounts of oligosaccharides 
(> 1 mg · mL-1) were detected in all samples from diabetics, both in 
FSMS and isCID mode. Also in this case, the above-mentioned con-
firmation methods can be used to discriminate dextran administration. 
No interferences were detected in the samples containing common 
doping agents.
CONCLUSIONS 
Urinary excretion profiles of HES and dextran have been investi-
gated with a “dilute-and-shoot” screening method by LC-HRMS by 
using different acquisition modes, investigating time-dependent de-
tectability of HES and dextran urinary oligosaccharide metabolites 
in post-administration. In isCID mode, HES was detected after 72 
hours, whereas dextran was present above the 500 µg · mL-1 thresh-
old up to 12 hours. Detection of multiple metabolites without isCID 
is related to recent administration of the PVE (24 hours).
[Glu2HE1-H20+H]+ and [Glu5HE3-H20+H]+ are suggested for 
HES to have optimal detectability. [Glu3+H-H2O]+can be used for 
semi-quantitative estimation of dextran. For the latter, thresholds of 
500 µg · mL-1 are suggested in isCID mode only.
Since the instrument acquires full scan spectra, the detection of 
HES or dextran in a suspicious sample can be pre-confirmed by 
post-screening monitoring of other metabolites or diagnostic ions, 
providing even more robust analytical results.
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